NOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock. NOX-100 is... NOX-100 is the first in a series of proprietary NO neutralizing compounds Medinox is developing to bind and inactivate NO, a simple gas molecule that is a key biological messenger in the body.
- Mechanism
- Curator reviewed
Under normal conditions, Nitric Oxide (NO) is produced in small amounts and plays many crucial maintenance roles including regulating blood pressure, facilitating memory and defending against pathogens. But when inflammation occurs, NO can be produced in excessive amounts and contributes to disease pathology.
NOX-100 binds excessive NO but do not remove the low levels needed to perform vital maintenance functions in the body. NOX-100 eliminates excessive NO which is distinct from enzyme inhibitors, which block NO synthesis.
- Primary indication
- Investigated for use/treatment in sepsis and septicemia.Curator reviewed
- Code names
- NOX-100
Resolves to
What you can answer from here — as of April 02, 2025
Which companies are running trials of NOX-100, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account